The FY2022 (Dec) proxy of Neurocrine Biosciences names 18 peer companies for pay. Among Neurocrine Biosciences and these peers, CEO pay was the lowest of 2 and total shareholder return was the highest of 2.
2nd highest of 2in Neurocrine Biosciences and its pay peers, FY2022 (Dec) by CEO pay:
$11.9M$16.7M
1st highest of 2in Neurocrine Biosciences and its pay peers, FY2022 (Dec) by total shareholder return:
$92$111
Pay peer group, FY2022 (Dec) proxy
| Incyte | ||
| ACADIA Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Alexion Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Alkermes plc | Not disclosed | Not disclosed |
| Alnylam Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| BeiGene, Ltd. | Not disclosed | Not disclosed |
| BioMarin Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Biohaven Ltd. | Not disclosed | Not disclosed |
| Exelixis, Inc. | Not disclosed | Not disclosed |
| Horizon Therapeutics plc | Not disclosed | Not disclosed |
| Ionis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Jazz Pharmaceuticals plc | Not disclosed | Not disclosed |
| Mirati Therapeutics, Inc. | Not disclosed | Not disclosed |
| Nektar Therapeutics | Not disclosed | Not disclosed |
| Sarepta Therapeutics, Inc. | Not disclosed | Not disclosed |
| Seagen Inc. | Not disclosed | Not disclosed |
| Ultragenyx Pharmaceutical Inc. | Not disclosed | Not disclosed |
| United Therapeutics Corporation | Not disclosed | Not disclosed |
18 companies
Changes by year
FY2025 (Dec) proxy
- AddedBiogenpay peer groupfollowing changes from our 2024 peer group: (i) the removal of Karuna Therapeutics, Inc. and Horizon Therapeutics plc due to acquisitions
- AddedModernapay peer groupfollowing changes from our 2024 peer group: (i) the removal of Karuna Therapeutics, Inc. and Horizon Therapeutics plc due to acquisitions
- RemovedHorizon Therapeutics plcpay peer groupfollowing changes from our 2024 peer group: (i) the removal of Karuna Therapeutics, Inc. and Horizon Therapeutics plc due to acquisitions
- RemovedKaruna Therapeutics, Inc.pay peer groupfollowing changes from our 2024 peer group: (i) the removal of Karuna Therapeutics, Inc. and Horizon Therapeutics plc due to acquisitions
%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M588%201715%20c-2%20-2%20-23%20-4%20-48%20-6%20-108%20-7%20-216%20-64%20-304%20-162%20l-56%20-61%200%2096%200%2097%20-32%203%20c-18%202%20-52%201%20-75%20-1%20l-43%20-3%200%20-589%20c0%20-554%201%20-589%2018%20-590%2036%20-2%20124%20-1%20127%203%202%201%205%20156%208%20343%205%20360%207%20386%2036%20471%2063%20178%20244%20284%20406%20236%2069%20-20%20119%20-58%20150%20-114%2041%20-75%2043%20-96%2044%20-575%20l1%20-363%2075%200%2075%200%200%2053%20c0%20215%209%20628%2015%20657%2022%20116%2064%20203%20124%20258%2020%2019%2065%2048%20101%2065%2053%2025%2076%2031%20132%2030%20121%200%20220%20-70%20248%20-173%2019%20-69%2021%20-128%2022%20-515%201%20-198%205%20-365%209%20-370%208%20-11%20119%20-12%20136%20-2%205%204%209%20168%208%20404%20-2%20333%20-5%20411%20-19%20478%20-43%20197%20-167%20313%20-349%20323%20-137%208%20-274%20-47%20-355%20-144%20-18%20-21%20-41%20-48%20-51%20-59%20-10%20-11%20-21%20-30%20-25%20-43%20-7%20-22%20-31%20-26%20-31%20-5%200%205%20-11%2032%20-25%2059%20-36%2071%20-109%20138%20-177%20164%20-55%2020%20-139%2040%20-145%2035z'/%3e%3cpath%20d='M63%20202%20c-38%20-2%20-53%20-7%20-57%20-20%20-6%20-19%200%20-61%2010%20-71%203%20-3%20111%20-6%20240%20-6%20256%200%20254%20-1%20254%2058%200%2015%20-6%2030%20-14%2033%20-16%206%20-352%2011%20-433%206z'/%3e%3cpath%20d='M680%20201%20c-30%20-4%20-37%20-14%20-36%20-49%201%20-17%209%20-31%2024%20-38%2025%20-12%20435%20-12%20465%201%2011%205%2017%2018%2017%2040%200%2022%20-6%2035%20-17%2040%20-19%207%20-409%2013%20-453%206z'/%3e%3cpath%20d='M1360%20202%20c-73%20-5%20-78%20-9%20-74%20-48%202%20-20%206%20-39%209%20-43%2010%20-9%20447%20-9%20473%200%2017%207%2022%2016%2022%2044%200%2021%20-6%2038%20-14%2041%20-15%206%20-356%2011%20-416%206z'/%3e%3c/g%3e%3c/svg%3e)
FY2024 (Dec) proxy
- AddedKaruna Therapeutics, Inc.pay peer groupfollowing changes from our 2023 peer group: (i) the removal of Biohaven Ltd. and Seagen Inc. due to acquisitions, (ii) the removal of Mirati Therapeutics, Inc., as its market capitalization and revenue fell below the targeted range
- AddedOrganon & Co.pay peer groupfollowing changes from our 2023 peer group: (i) the removal of Biohaven Ltd. and Seagen Inc. due to acquisitions, (ii) the removal of Mirati Therapeutics, Inc., as its market capitalization and revenue fell below the targeted range
- RemovedBiohaven Ltd.pay peer groupfollowing changes from our 2023 peer group: (i) the removal of Biohaven Ltd. and Seagen Inc. due to acquisitions, (ii) the removal of Mirati Therapeutics, Inc., as its market capitalization and revenue fell below the targeted range
- RemovedMirati Therapeutics, Inc.pay peer groupfollowing changes from our 2023 peer group: (i) the removal of Biohaven Ltd. and Seagen Inc. due to acquisitions, (ii) the removal of Mirati Therapeutics, Inc., as its market capitalization and revenue fell below the targeted range
- RemovedSeagen Inc.pay peer groupfollowing changes from our 2023 peer group: (i) the removal of Biohaven Ltd. and Seagen Inc. due to acquisitions, (ii) the removal of Mirati Therapeutics, Inc., as its market capitalization and revenue fell below the targeted range
FY2023 (Dec) proxy
- RemovedAlexion Pharmaceuticals, Inc.pay peer groupfollowing changes from our 2022 peer group: (i) the removal of Alexion Pharmaceuticals, Inc., due to its acquisition by AstraZeneca
- RemovedNektar Therapeuticspay peer groupfollowing changes from our 2022 peer group: (i) the removal of Alexion Pharmaceuticals, Inc., due to its acquisition by AstraZeneca
FY2022 (Dec) proxy
- AddedBiohaven Ltd.pay peer groupfollowing changes from our 2021 peer group, all of which were recommended by Aon and approved by our Committee: (i) the removal of bluebird bio, Inc., which no longer met the criteria above
- AddedMirati Therapeutics, Inc.pay peer groupfollowing changes from our 2021 peer group, all of which were recommended by Aon and approved by our Committee: (i) the removal of bluebird bio, Inc., which no longer met the criteria above
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.